Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases
Every reference with a DOI in the deposited reference list resolved to a known
work in Crossref or DataCite at the dated check, and none carried a retraction,
withdrawal, or removal notice.
7 without a DOI — not checked. A reference
deposited without a DOI is never matched by title or guessed at; it stays outside the checked
set, and this line discloses that.
Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations Between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
A micropapillary pattern is predictive of a poor prognosis in lung adenocarcinoma, and reduced surfactant apoprotein A expression in the micropapillary pattern is an excellent indicator of a poor prognosis
Mucinous and Nonmucinous Bronchioloalveolar Adenocarcinomas Have Distinct Staining Patterns With Thyroid Transcription Factor and Cytokeratin 20 Antibodies
Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib
Mucinous Differentiation Correlates with Absence of EGFR Mutation and Presence of KRAS Mutation in Lung Adenocarcinomas with Bronchioloalveolar Features
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours
Micropapillary pattern: a distinct pathological marker to subclassify tumours with a significantly poor prognosis within small peripheral lung adenocarcinoma (≤20 mm) with mixed bronchioloalveolar and invasive subtypes (Noguchi's type C tumours)
IFCT-0401 Trial: A Phase II Study of Gefitinib Administered as First-Line Treatment in Advanced Adenocarcinoma with Bronchioloalveolar Carcinoma Subtype
Bronchioloalveolar carcinomas. Cell types, patterns of growth, and prognostic correlates
The 7 references without a DOI — listed, not checked
no DOI — not checked10.1038/modpathol.2010.232_bib1
no DOI — not checkedCohen PR, Yoshizawa A, Motoi N, et al. Signet ring cell features (SRCF) in lung adenocarcinoma: a cytologic feature or a histologic subtype? Mod Pathol 2010;23.
no DOI — not checkedDeshpande CG, Yoshizawa A, Motoi N, et al. Clear cell change in lung adenocarcinoma: a cytologic change rather than a histologic variant. Mod Pathol 2009;22.
no DOI — not checked10.1038/modpathol.2010.232_bib22
no DOI — not checkedLung
no DOI — not checked10.1038/modpathol.2010.232_bib26
no DOI — not checkedHayes DF, Allred C, Anderson BO, et al. Breast. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds), AJCC Cancer Staging Manual, 7th edn, Springer: New York, 2009.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-08-16 — re-checked daily as this page is visited;
titles and statuses come from Crossref and DataCite and are not part of the signed record
Both snippets point at the live badge image and link back to this page. The
badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.